Peptide therapy belief claims: What the science actually supports

What did @primal_gains actually say?

The creator's core argument is simple: peptides are too new, there's no long-term research on them, and you shouldn't put experimental things in your body. They also spent significant time on SARMs, arguing that everyone who took them ended up with suppressed testosterone requiring TRT-level intervention. The peptide warning was essentially one sentence: "there is no long-term research on peptides because they're new."

To be fair, they're not promoting anything here. They're urging caution. That's a more responsible position than most fitness influencers take. But lumping SARMs and peptides together as if they carry identical risk profiles is a meaningful error, and it's worth unpacking why.

Does the science back this up?

The long-term safety concern is legitimate, but the framing overstates how new peptide research actually is. BPC-157, for instance, has been studied in animal models since at least the early 1990s. Sikiric et al. published preclinical work on BPC-157's gastrointestinal and wound-healing effects in the late 1990s and early 2000s in journals like Life Sciences and Journal of Physiology. That's not "new." What's new is widespread consumer use outside clinical settings.

The SARMs claim is better supported. A 2020 paper by Bhasin et al. in the New England Journal of Medicine and multiple FDA warnings document significant hormonal suppression, liver toxicity, and cardiovascular risk with SARMs. The creator's characterization that users ended up needing TRT is consistent with documented cases of prolonged HPG axis suppression post-SARM use. That part checks out.

Where the creator goes wrong is treating peptides as a monolithic category. GHK-Cu, a copper-binding tripeptide, operates through completely different mechanisms than a growth hormone secretagogue like ipamorelin. Grouping them as one risk category isn't accurate.

What did they get wrong (or right)?

They got the SARMs warning right. SARMs were aggressively marketed as side-effect-free alternatives to anabolic steroids, and that turned out to be false. The FDA has issued multiple warnings since 2017, and case reports of severe liver injury and sustained testosterone suppression are well-documented. Saying "everybody who took SARMs ended up messed up" is an overstatement, but the directional concern is accurate.

What they got wrong is the implicit equivalence between SARMs and peptides. SARMs bind androgen receptors and directly interfere with the hypothalamic-pituitary-gonadal axis. Most therapeutic peptides don't. BPC-157 doesn't bind androgen receptors. TB-500 (thymosin beta-4) works on actin regulation. These are not comparable mechanisms.

• The creator also ignores that some peptides, like oxytocin and insulin, are already FDA-approved and have decades of clinical data.
• The claim that peptides are universally "experimental" ignores that peptide-based drugs represent one of the fastest-growing classes in pharmaceutical development, with over 60 FDA-approved peptide drugs on the market as of 2022 (Muttenthaler et al., Nature Reviews Drug Discovery, 2021).
• That said, research-grade or compounded peptides used in bodybuilding contexts are a different matter and do lack robust long-term human safety data.

What should you actually know?

The creator's instinct, that you should be cautious about substances without long-term human safety data, is reasonable. But the execution conflates very different compounds. Here's what the evidence actually says.

Peptides used in performance and recovery contexts, particularly BPC-157 and TB-500, have mostly preclinical (animal) data supporting their proposed mechanisms. Human clinical trials are limited. That's a real gap. A 2022 review in Frontiers in Pharmacology noted that while preclinical BPC-157 data is promising, controlled human trials are largely absent from the published literature.

For growth hormone secretagogues like ipamorelin and CJC-1295, there is more human data. Raun et al. published on ipamorelin's GH-releasing properties in humans in European Journal of Endocrinology in 1998. But long-term cardiovascular and oncological effects of sustained GH elevation are a legitimate concern, and no long-term studies in healthy adults have resolved that question.

The practical takeaway: the creator's blanket "don't take peptides" advice is too broad to be clinically useful, but the underlying concern about insufficient long-term human data for most peptides used in optimization contexts is real and not fully answered by existing research.